Search results

1 – 3 of 3
Per page
102050
Citations:
Loading...
Access Restricted. View access options
Article
Publication date: 7 February 2020

Dumilah Ayuningtyas, Raden Roro Mega Utami and Asri Nur Maulidya

The Regulation of the Minister of Justice and Human Rights of the Republic of Indonesia No 34, 2016 was issued to regulate the criteria of districts/municipalities care about…

91

Abstract

Purpose

The Regulation of the Minister of Justice and Human Rights of the Republic of Indonesia No 34, 2016 was issued to regulate the criteria of districts/municipalities care about human rights. Anak-Dalam Tribe (Suku Anak Dalam – SAD), a remote indigenous community in Batanghari, Jambi Province, faces its own challenges in health services. This study aims to assess the readiness of Batanghari as the District of Human Rights Care to fulfill the health care of SAD.

Design/methodology/approach

Using qualitative approach, this study explored the viewpoints of relevant stakeholders equipped with secondary data, literature review and analysis of relevant news in mass media as a form of triangulation.

Findings

Generally, Batanghari District Government has fulfilled the criteria of preparedness of the District of Human Rights Care about the distribution of health services. Nevertheless, there are still obstacles, such as difficulties in registering the SAD community – the Residence Registration Number and the strong customs in SAD's beliefs and traditions. Local government tries to overcome these problems with affirmative policies that facilitate member of the SAD community.

Originality/value

This study was supported by the Directorate of Research and Community Service of Universitas Indonesia. The authors have no conflicts of interest with the material presented in this manuscript. The authors declare that no ethical issues may arise after the publication of this manuscript.

Details

International Journal of Human Rights in Healthcare, vol. 13 no. 3
Type: Research Article
ISSN: 2056-4902

Keywords

Access Restricted. View access options
Article
Publication date: 31 May 2019

Ria Christine Siagian, Besral Besral, Anhari Achadi and Dumilah Ayuningtyas

The World Health Organization has pointed out that the majority of developing countries currently rely on imported drugs, in spite of the fact that there is potential for them to…

274

Abstract

Purpose

The World Health Organization has pointed out that the majority of developing countries currently rely on imported drugs, in spite of the fact that there is potential for them to produce their own drugs. The purpose of this paper is to present a framework as an innovation policy model that can strategically predict the outcome of drug development investment in developing countries.

Design/methodology/approach

In order to explore a model relevant to the policy-making process, the literature was systematically reviewed with a focus on the impact of policy changes on drug development in developing countries.

Findings

An innovation policy model consists of the relational influences of contextual variables of pharma capabilities, innovation incentives and political factors affecting drug development in developing countries, derived from a dissenting policy-making perspective. This was built to test two hypotheses of a positive relationship between the above variables; and a perspectives gap between the pharmaceutical companies and the policymakers. These hypotheses address issues related to the lack of drug development in developing countries.

Research limitations/implications

This paper presents a conceptual framework for the evaluation and provides examples of its use, but it is currently at a relatively early stage of research. Further work is currently underway and will later be presented to the same journal.

Social implications

Domestic drug development in developing countries needs to be feasible in order to ensure drug security. This predictive policy model provides a comprehensive approach to health policy reforms to examine innovation strategies.

Originality/value

This model includes measures to explore whether pharma capabilities, innovation incentives and/or political factors have an effect on domestic drug development in developing countries. It bridges the policy implementation’s operational process between pharmaceutical companies and policymakers.

Details

International Journal of Health Governance, vol. 24 no. 2
Type: Research Article
ISSN: 2059-4631

Keywords

Access Restricted. View access options
Article
Publication date: 27 March 2020

Ria Christine Siagian, Anhari Achadi, Hasbullah Thabrany, Dumilah Ayuningtyas, Prastuti Soewondo, Sutanto Priyo Hastono, Purnawan Junadi, Novilia Sjafri Bachtiar and Tepy Usia

The pharmaceutical industry in Indonesia appears hesitant to make the transition from inventor to innovator and instead continues with the process of formulation and packaging…

256

Abstract

Purpose

The pharmaceutical industry in Indonesia appears hesitant to make the transition from inventor to innovator and instead continues with the process of formulation and packaging. Evidence-based policy has been advocated for Indonesia and, in general, this is more likely to hold. This study aims to establish a model for a policy-making process that is strategically able to predict strategies that would encourage drug development in Indonesia.

Design/methodology/approach

A quantitative approach with the survey method was designed to obtain appropriate data from a population of pharmaceutical industries in Indonesia and relevant government institutions to assess the relationship of various factors capable of triggering domestic drug development, including pharma capability, political feasibility and innovation incentives. The construct was validated using a set of techniques pertaining to the calculation of structural equation modeling.

Findings

The model demonstrates how it matters when applied to the policy-making process. It proves that pharma capability, political feasibility, and innovation incentives correlated to pharma capability are major catalysts in the promotion of drug development. These are largely explained by market opportunity, pull factors, government power, and position. Although all of the elements were moderately to strongly related to the promotion of drug development, this study has revealed the predictive impact on drug development in Indonesia to be only 46%.

Originality/value

This study adds values to policy-makers as it attempts to predict strategies that would encourage a successful policy when being implemented. Encompassing both pharma industries and government institutions, this study captures a real situation and provides an empirical contribution to the concept of the integrated research of drug development in developing countries.

Details

International Journal of Health Governance, vol. 25 no. 2
Type: Research Article
ISSN: 2059-4631

Keywords

1 – 3 of 3
Per page
102050